AstraZeneca shareholders are being advised to oppose the pay plan for the company's CEO, Pascal Soriot. This advice comes amid discussions about the company's financial status. Shareholders are urged to consider the implications of the CEO's remuneration plan in the context of the company's overall performance. The call to oppose the pay plan is indicative of the shareholders' concerns about AstraZeneca's approach to executive compensation.